Replies to post #251013 on Biotech Values

[shareholder_boar]

I'm no jim but that link connects to the article for me. Also available as a 46 page .pdf

https://www.cell.com/cell-reports/pdfExtended/S2211-1247(24)00226-2

CRVS moved up nicely not long after he posted
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=CRVS&insttype=Stock&freq=9&show=&time=1

[biotech jim]

Try this information, and please note that I am only an amateur immunologist:

NR4a1/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment
Tanakorn Srirat
Taeko Hayakawa
Setsuko Mise-Omata
Shigeyuki Shichino
Minako Ito
Akihiko Yoshimura

Highlights
•
The deletion of NR4a1/2 in T cells enhances anti-tumor immunity
•
Loss of NR4a1/2 increases TCF1+ stem-like precursors of exhausted CD8+ T cells
•
Lack of NR4a1/2 in T cells promotes glycolysis and oxidative phosphorylation
•
NR4a1/2-deficient T cells enhance persistence in the tumor microenvironment